CN115386643A - 一种基于抗炎基因定制护肤品的方法与护肤品 - Google Patents
一种基于抗炎基因定制护肤品的方法与护肤品 Download PDFInfo
- Publication number
- CN115386643A CN115386643A CN202210994724.7A CN202210994724A CN115386643A CN 115386643 A CN115386643 A CN 115386643A CN 202210994724 A CN202210994724 A CN 202210994724A CN 115386643 A CN115386643 A CN 115386643A
- Authority
- CN
- China
- Prior art keywords
- skin care
- care product
- skin
- oligopeptide
- hexapeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 46
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 title claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000003255 anti-acne Effects 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 201000008937 atopic dermatitis Diseases 0.000 claims description 9
- 239000004475 Arginine Substances 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 229960003121 arginine Drugs 0.000 claims description 8
- 208000010668 atopic eczema Diseases 0.000 claims description 8
- 208000001875 irritant dermatitis Diseases 0.000 claims description 8
- -1 polydimethylsiloxane Polymers 0.000 claims description 8
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 8
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 7
- 235000001014 amino acid Nutrition 0.000 claims description 7
- 229940024606 amino acid Drugs 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 6
- 108020004414 DNA Proteins 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 6
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 230000003712 anti-aging effect Effects 0.000 claims description 5
- 230000003266 anti-allergic effect Effects 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- 239000002738 chelating agent Substances 0.000 claims description 5
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 claims description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 5
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 239000004519 grease Substances 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 229960002591 hydroxyproline Drugs 0.000 claims description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 5
- 229960000310 isoleucine Drugs 0.000 claims description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000002562 thickening agent Substances 0.000 claims description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- 239000004474 valine Substances 0.000 claims description 5
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 claims description 4
- 102000049772 Interleukin-16 Human genes 0.000 claims description 4
- 101800003050 Interleukin-16 Proteins 0.000 claims description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- 108010077895 Sarcosine Proteins 0.000 claims description 4
- 241001506047 Tremella Species 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 229940094978 bis-peg-18 methyl ether dimethyl silane Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- 229940043230 sarcosine Drugs 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 claims description 3
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 3
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 3
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 3
- 101001121371 Homo sapiens Putative transcription factor Ovo-like 1 Proteins 0.000 claims description 3
- 101000635958 Homo sapiens Transforming growth factor beta-2 proprotein Proteins 0.000 claims description 3
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 3
- 229920002305 Schizophyllan Polymers 0.000 claims description 3
- 241001369613 Stephania tetrandra Species 0.000 claims description 3
- 229960005305 adenosine Drugs 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 235000020958 biotin Nutrition 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 235000000639 cyanocobalamin Nutrition 0.000 claims description 3
- 239000011666 cyanocobalamin Substances 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- 229960003067 cystine Drugs 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 3
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- 229940032094 squalane Drugs 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- OGNHOGPWQTWKGQ-VGWMRTNUSA-N (2S)-5-amino-2-[[(2S)-1-[2-[[(2S)-5-amino-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 OGNHOGPWQTWKGQ-VGWMRTNUSA-N 0.000 claims description 2
- GFEYWOGCSROPRT-OBXVVNIGSA-N (2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=CC=C1 GFEYWOGCSROPRT-OBXVVNIGSA-N 0.000 claims description 2
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims description 2
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 claims description 2
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 claims description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 2
- ITIMHIATVYROGF-XWUOBKMESA-N (3S)-3-[[(2S)-2-acetamido-6-aminohexanoyl]amino]-4-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-oxobutanoic acid Chemical compound CC(C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(C)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O ITIMHIATVYROGF-XWUOBKMESA-N 0.000 claims description 2
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 2
- 229920002498 Beta-glucan Polymers 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 2
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 claims description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 2
- 108010087806 Carnosine Proteins 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- 244000308760 Helichrysum petiolatum Species 0.000 claims description 2
- 101000686909 Homo sapiens Resistin Proteins 0.000 claims description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 102100033467 L-selectin Human genes 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- 239000004909 Moisturizer Substances 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 2
- 108010047657 Phe-Val-Ala-Pro-Phe-Pro Proteins 0.000 claims description 2
- 102100026326 Putative transcription factor Ovo-like 1 Human genes 0.000 claims description 2
- 102100024735 Resistin Human genes 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 102100030737 Transforming growth factor beta-2 proprotein Human genes 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 2
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 claims description 2
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 235000009582 asparagine Nutrition 0.000 claims description 2
- 229960001230 asparagine Drugs 0.000 claims description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 2
- 229960003237 betaine Drugs 0.000 claims description 2
- 229940044199 carnosine Drugs 0.000 claims description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims description 2
- 230000003750 conditioning effect Effects 0.000 claims description 2
- 229960002104 cyanocobalamin Drugs 0.000 claims description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 235000019197 fats Nutrition 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 2
- 229940119170 jojoba wax Drugs 0.000 claims description 2
- PEUSZTDUWXURQK-BZRHSMGTSA-N methyl (2s)-2-[[(2s)-2-[[(3s,4s)-4-[[(2s)-2-[[2-[[(2s)-2-amino-3-phenylpropanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]-3-hydroxy-6-methylheptanoyl]amino]propanoyl]amino]-3-phenylpropanoate Chemical compound C([C@@H](C(=O)OC)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CC=CC=C1 PEUSZTDUWXURQK-BZRHSMGTSA-N 0.000 claims description 2
- 230000001333 moisturizer Effects 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 claims description 2
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 claims description 2
- 108010030856 phenylalanyl-glycyl-valyl-statyl-alanyl-phenylalanine methyl ester Proteins 0.000 claims description 2
- 235000008160 pyridoxine Nutrition 0.000 claims description 2
- 239000011677 pyridoxine Substances 0.000 claims description 2
- 229960003471 retinol Drugs 0.000 claims description 2
- 235000020944 retinol Nutrition 0.000 claims description 2
- 239000011607 retinol Substances 0.000 claims description 2
- 229940057910 shea butter Drugs 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- PSWFFKRAVBDQEG-YGQNSOCVSA-N thymopentin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PSWFFKRAVBDQEG-YGQNSOCVSA-N 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- OWVLYQRCCIEOPF-QHTZZOMLSA-L zinc;(2s)-5-oxopyrrolidine-2-carboxylate Chemical compound [Zn+2].[O-]C(=O)[C@@H]1CCC(=O)N1.[O-]C(=O)[C@@H]1CCC(=O)N1 OWVLYQRCCIEOPF-QHTZZOMLSA-L 0.000 claims description 2
- 229940105990 diglycerin Drugs 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 229940094541 polyglycerin-10 Drugs 0.000 claims 1
- 229940099549 polyglycerin-3 Drugs 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 58
- 206010000496 acne Diseases 0.000 abstract description 14
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 13
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 206010040830 Skin discomfort Diseases 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 3
- 210000002615 epidermis Anatomy 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 239000011148 porous material Substances 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 230000008929 regeneration Effects 0.000 abstract description 3
- 238000011069 regeneration method Methods 0.000 abstract description 3
- 230000008439 repair process Effects 0.000 abstract description 3
- 238000001514 detection method Methods 0.000 description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- 230000037307 sensitive skin Effects 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 102100028314 Filaggrin Human genes 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 230000005808 skin problem Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- 229940035893 uracil Drugs 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 2
- 101710088660 Filaggrin Proteins 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 101150012407 OVOL1 gene Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 101150073296 SELL gene Proteins 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 101150072275 TGFB2 gene Proteins 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 229920013818 hydroxypropyl guar gum Polymers 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 241000197194 Bulla Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 108010092694 L-Selectin Proteins 0.000 description 1
- 102000016551 L-selectin Human genes 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 102210016770 rs7531806 Human genes 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/606—Nucleosides; Nucleotides; Nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/737—Galactomannans, e.g. guar; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/49—Solubiliser, Solubilising system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Botany (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Cosmetics (AREA)
Abstract
本发明涉及一种基于抗炎基因定制护肤品的方法与护肤品，通过基因测序技术，分析特定基因序列的单核苷酸多态性(SNP)，通过精准的基因位点进行皮肤肤质遗传信息的解读，全面解析受试者肌肤功能生理状态以及各种因素下可能出现的肤质问题，可以根据检测结果选择定制的护肤品。本发明的护肤品具有抗炎修复、增强免疫力、平衡润养、预防敏感、调节水油平衡、净化毛孔，抑制炎症，预防痘痘生成，减少肌肤不适，挺好肌肤耐受性，促进表皮新生修复的优点。
Description
技术领域
本发明涉及护肤品技术领域，尤其涉及一种基于抗炎基因定制护肤品的方法与护肤品。
背景技术
随着科学技术的发展，人类的全基因谱图已经可以通过测序获得。当前大量的研究表明，人类皮肤的状态与基因有着密切的关系。这些皮肤相关基因中特定位点的基因型(或基因单核苷酸多态性，SNPs，简称基因多态性)可以很大程度上影响着皮肤的状态，不同的基因型是导致皮肤出现问题的关键因素。人们可以通过检测不同基因型，发现或预测皮肤的问题，并以此作为指导选择合适的护肤品。进一步研究发现，除基因型外，由基因型导致的表达蛋白才是导致皮肤问题的关键因素。
目前市场上存在着大量具有不同功能的护肤和美容产品供人们选择。但是每个个体的皮肤都具有其独特性，如何选择适合自己的护肤品就是人们面临的一个重要问题。当前消费者普遍选用的方法就是采用选择-购买-尝试的方式验证护肤品是否适合自己，在此过程中消费者不仅浪费了大量的时间和财力，而且还可能会造成皮肤的不适，如出现过敏等现象。因此如何选择适合消费者个体的护肤品，成为亟待解决的一个重要问题。
皮肤敏感，医学上普遍认为不是皮肤疾病，是指对多种因素易感而诱发的主观感觉症状的皮肤状态，即皮肤反应性高、耐受性差甚至易过敏。敏感皮肤主要发生于面部，还有手脚、头皮等其他部位。就日常状态而言，敏感皮肤并无客观皮损或皮肤疾病证据，主要特点是更为干燥、容易紧绷和发红；受到轻微刺激，即可产生瘙痒、脱屑甚至烧灼和刺痛等感觉，严重者可产生不良情绪或精神症状。气候变化、空气污染及化妆品种类与成分复杂化，提高了敏感皮肤出现及接受刺激的可能性。
皮肤炎症，是指对多种因素易感而诱发的主观感觉症状的皮肤状态，即皮肤反应性高、耐受性差甚至易过敏。敏感皮肤主要发生于面部。就日常状态而言，敏感皮肤并无客观皮损或皮肤疾病证据，主要特点是更为干燥、容易紧绷和发红；受到轻微刺激，即可产生瘙痒、红肿甚至烧灼和刺痛等感觉。
发明内容
本发明提供了一种基于基于抗炎基因定制护肤品的方法与护肤品，良好的抗炎能力取决于肌体对抗各种过敏因素引起的变态反应性皮炎，对抗各种内分泌、外部刺激、心理因素等导致痤疮，以及激素性皮炎。
为了实现上述目的，本发明采用以下技术方案：
一种基于抗炎基因定制护肤品的方法，包括采集用户细胞样本、提取DNA并检测DNA中抗衰老相关基因的多态性，所述的抗炎相关基因包括抗痤疮能力相关基因、抗刺激性皮炎能力相关基因与抗过敏性皮炎能力相关基因。
作为优选，所述的抗痤疮能力相关基因包括RETN、OVOL1、TGFB2与SELL。
作为优选，所述的抗刺激性皮炎能力相关基因包括FLG与TNF。
作为优选，所述的抗过敏性皮炎能力相关基因包括IL16与TNF。
一种上述的基于抗炎基因定制的护肤品，所述护肤品的原料按重量份数计包括保湿剂5-10重量份、油脂0.5-6重量份、氨基酸0.1-5重量份、多肽类0.1-6重量份、增溶剂0.2-2重量份、增稠剂0.1-1重量份、皮肤调理剂0.5-5重量份、螯合剂0.1-0.2重量份与水70-90重量份。
作为优选，所述保湿剂包含透明质酸钠、水解透明质酸钠、银耳多糖、石斛多糖、β-葡聚糖、海藻糖、甜菜碱、丙二醇、丁二醇、1,2-戊二醇、1,2-己二醇、甘油、双甘油、聚甘油-3、聚甘油-10、甘油聚醚-26、聚季铵盐-51；所述油脂包含角鲨烷、聚二甲基硅氧烷、双-PEG-18甲基醚二甲基硅烷、双-PEG-15甲基醚聚二甲基硅氧烷、橄榄油、霍霍巴油、牛油果树果脂的一种或多种；所述氨基酸包括酪氨酸、苯丙氨酸、胱氨酸、半胱氨酸、色氨酸、肌氨酸、赖氨酸、羟脯氨酸、蛋氨酸、组氨酸、精氨酸、天冬氨酸、苏氨酸、丝氨酸、谷氨酸、脯氨酸、甘氨酸、丙氨酸、缬氨酸、异亮氨酸、亮氨酸、天冬酰胺、谷氨酰胺、葡糖胺、软骨素硫酸钠、吡哆素、生物素、牛磺酸、视黄醇、叶酸、核黄素、烟酰胺、氰钴胺的一种或多种；所述多肽包含寡肽-1、寡肽-2、寡肽-3、寡肽-4，寡肽-5、寡肽-6，肌肽，腺苷，三肽-1、三肽-1铜、三肽-3、五肽-1、五肽-3、六肽-1、六肽-3、六肽-5、六肽-9、六肽-11、九肽-1、棕榈酰三肽-1、棕榈酰三肽-5、乙酰基六肽-8、谷胱甘肽、精氨酸/赖氨酸多肽、棕榈酰四肽-7、乙酰基四肽-2、棕榈酰四肽-2、棕榈酰五肽-4、酵母菌多肽类中的一种或几种的组合。
作为优选，针对用户的抗痤疮能力选择加入苦参根提取物与PCA锌。
作为优选，针对用户的抗刺激性皮炎能力选择加入裂裥菌素。
作为优选，针对用户的抗过敏性皮炎能力选择加入意大利腊菊提取物与粉防己提取物。
本发明基于现有的采集用户细胞样本、提取mRNA、反转录合成cDNA与检测cDNA中抗衰老相关基因的多态性及对应cDNA的表达量方法，检测出于抗衰老相关基因。
抗痤疮能力，痤疮是一种毛囊皮脂腺的慢性炎症性皮肤病。主要与雄激素分泌增多、皮脂分泌增多、毛囊皮脂腺导管角化异常、痤疮丙酸杆菌增多及免疫失衡有关。基因SELL编码L-选择素蛋白，可促进白细胞迁移到炎症部位，帮助消炎，促进伤口愈合，从而降低痘痘发生的可能性及严重度。rs7531806位点位于SELL基因附近，可能与SELL基因功能相关，通过对1303名和1860名重型痘痘患者的GWAS研究显示，当该位点为AA时，抗痘(痤疮)能力更弱。
基因OVOL1编码锌指蛋白，缺少该蛋白可能加速皮肤细胞的老化和死亡，而过多的老化死亡细胞从皮肤毛囊口排除体外时，极易造成堵塞，使抗痘(痤疮)能力降低。rs478304位点位于OVOL1基因附近，可能通过影响OVOL1基因的表达量，影响抗痘(痤疮)能力。通过对2001名重型痘痘患者的GWAS研究显示，当该位点为TT时，抗痘(痤疮)能力更弱。
基因TGFB2编码转化生长因子配体，它的功能之一是通过与免疫细胞相互作用，调节炎症反应的过程，影响抗痘(痤疮)能力。rs1159268位点位于TGFB2基因附近，可能通过影响TGFB2基因的表达量，影响抗痘(痤疮)能力。通过对2001名重型痘痘患者的GWAS研究显示，当该位点为AA时，抗痘(痤疮)能力更弱。
抗刺激性皮炎能力，刺激性皮炎是指皮肤接触刺激性物质以后发生的皮肤损害，急性皮炎主要表现为皮肤红斑、水肿、脱屑和角质形成细胞囊泡化样变，慢性皮炎主要表现为皮肤裂隙、苔藓化和角质过度。某些FLG变异会导致聚丝蛋白的减少或丢失，导致对慢性ICD的敏感性增加以及对金属(如镍)的接触敏感。聚丝蛋白在维持皮肤的表皮结构很重要，还参与炎症反应。
抗过敏性皮炎能力，过敏性皮炎是指皮肤接触过敏原以后产生的炎症反应，主要症状为出现红斑、肿胀、丘疹、水疱、甚至大疱。白细胞介素16(IL-16)是一种免疫调节性细胞因子，其与炎症反应机制相关，其多态性位点会导致炎症调节能力变弱，导致过敏反应。
本发明的有益效果是：本发明通过基因测序技术，分析特定基因序列的单核苷酸多态性(SNP)，通过精准的基因位点进行皮肤肤质遗传信息的解读，全面解析受试者肌肤功能生理状态以及各种因素下可能出现的肤质问题，可以根据检测结果选择定制的护肤品。本发明的护肤品具有抗炎修复、增强免疫力、平衡润养、预防敏感、调节水油平衡、净化毛孔，抑制炎症，预防痘痘生成，减少肌肤不适，挺好肌肤耐受性，促进表皮新生修复的优点。
附图说明
图1是受试者面部图像采集。
具体实施方式
为详细说明本发明的技术内容、所实现目的及效果，以下结合实施方式予以说明。
除非另有定义，所有于此处所使用的技术性及科学性术语具有的意义，对于属于本发明的技术领域中技术人员为常识。当于此处使用时，以下术语具有其所属的意义，除非另有特别定义。
本发明中，采集用户细胞样本、提取DNA并检测DNA中抗衰老相关基因的多态性，检测出于抗炎相关基因是属于现有技术。
实施例1
本实施例1针对37岁的志愿者1进行基因检测，抗过敏性皮炎能力。
依据检测结果为其配制如下配方的护肤品：其中，护肤品总质量为共100Kg
保湿剂：透明质酸钠0.2Kg、聚甘油-10 0.2Kg、甘油聚醚-26 8Kg；
油脂：双-PEG-18甲基醚二甲基硅烷2Kg；
氨基酸：酪氨酸0.2Kg、苯丙氨酸0.2Kg、色氨酸0.2Kg、赖氨酸0.2Kg、羟脯氨酸0.2Kg、组氨酸0.2Kg、精氨酸0.2Kg、天冬氨酸0.2Kg、苏氨酸0.2Kg、丝氨酸0.2Kg、谷氨酸0.2Kg、脯氨酸0.2Kg、甘氨酸0.2Kg、丙氨酸0.2Kg、缬氨酸0.2Kg、异亮氨酸0.2Kg、亮氨酸0.2Kg、生物素0.2Kg、叶酸0.2Kg；
多肽：寡肽-1 0.2Kg、寡肽-2 0.2Kg、寡肽-3 0.2Kg、腺苷0.2Kg，三肽-1 0.2Kg、三肽-1铜0.2Kg、六肽-11 0.1Kg；
增溶剂：聚甘油-10月桂酸酯0.2Kg；
增稠剂：羟丙基瓜尔胶0.2Kg；
皮肤调理剂：尿嘧啶0.2Kg、黄嘌呤0.2Kg、胸腺嘧啶0.2Kg、意大利腊菊提取物2Kg、粉防己提取物2Kg；
螯合剂：EDTA二钠0.2Kg；其他：水余量。
实施例1的使用者1在使用前经常长痘，在使用2周后痘痘减少，使用4周后基本不长痘，使用6周后不长痘，使用8周后不长痘且痘印减少。
实施例2
本实施例2针对42岁的志愿者2进行基因检测，抗痘(痤疮)能力。
依据检测结果为其配制如下配方的护肤品：其中，护肤品总质量为共100Kg，
保湿剂：银耳多糖0.2Kg、丙二醇1.8Kg、1,2-戊二醇3Kg；
油脂：双-PEG-18甲基醚二甲基硅烷0.5Kg；
氨基酸：酪氨酸0.2Kg、苯丙氨酸0.2Kg、色氨酸0.2Kg、肌氨酸0.2Kg、赖氨酸0.2Kg、羟脯氨酸0.2Kg、蛋氨酸0.2Kg、组氨酸0.2Kg、精氨酸0.2Kg、天冬氨酸0.2Kg、苏氨酸0.2Kg、丝氨酸0.2Kg、谷氨酸0.2Kg、脯氨酸0.2Kg、甘氨酸0.2Kg、丙氨酸0.2Kg、缬氨酸0.2Kg、异亮氨酸0.2Kg、亮氨酸0.2Kg、氰钴胺0.2Kg；
多肽：寡肽-1 0.2Kg、寡肽-2 0.2Kg、寡肽-3 0.2Kg、五肽-1 0.2Kg、五肽-30.2Kg、六肽-1 0.2Kg、六肽-3 0.2Kg、六肽-5 0.2Kg、六肽-9 0.2Kg、六肽-11 0.2Kg；
增溶剂：聚山梨醇酯-20 0.2Kg；
增稠剂：羟丙基瓜尔胶0.5Kg；
皮肤调理剂：尿嘧啶0.5Kg、黄嘌呤0.5Kg、胸腺嘧啶0.5Kg、PCA锌1.5Kg；
螯合剂：EDTA二钠0.2Kg；其他：水余量。
实施例3
本发明实施例3针对45岁的志愿者3进行基因检测，抗刺激性皮炎能力。
依据检测结果为其配制如下配方的护肤品：其中，护肤品总质量为共100Kg，
保湿剂：透明质酸钠0.5Kg、水解透明质酸钠0.5Kg、银耳多糖0.5Kg、丁二醇8Kg；
油脂：角鲨烷2Kg、聚二甲基硅氧烷2Kg；
氨基酸：酪氨酸0.2Kg、苯丙氨酸0.2Kg、胱氨酸0.2Kg、半胱氨酸0.2Kg、色氨酸0.2Kg、肌氨酸0.2Kg、赖氨酸0.2Kg、羟脯氨酸0.2Kg、蛋氨酸0.2Kg、组氨酸0.2Kg、精氨酸0.2Kg、天冬氨酸0.2Kg、苏氨酸0.2Kg、丝氨酸0.2Kg、谷氨酸0.2Kg、脯氨酸0.2Kg、甘氨酸0.2Kg、丙氨酸0.2Kg、缬氨酸0.2Kg、异亮氨酸0.2Kg、亮氨酸0.2Kg、核黄素0.2Kg；
多肽：寡肽-1 0.2Kg、寡肽-2 0.2Kg、寡肽-3 0.2Kg、寡肽-4 0.2Kg、寡肽-50.2Kg、寡肽-6 0.2Kg、精氨酸/赖氨酸多肽0.2Kg、棕榈酰四肽-2 0.2Kg；
增溶剂：聚山梨醇酯-80 1Kg、聚甘油-10月桂酸酯1Kg；
增稠剂：羟乙基纤维素0.2Kg；
皮肤调理剂：尿嘧啶0.2Kg、黄嘌呤0.2Kg、胸腺嘧啶0.2Kg、裂裥菌素4.4Kg；
螯合剂：EDTA二钠0.15Kg；其他：水余量。
对实施例2的使用者2与实施例3的使用者3使用Visia-CR对受试者进行面部图像采集，再用Image Pro Plus图像分析软件分析图片选定区域的皮肤颜色(红-绿)值，测试值越小，说明皮肤颜色越不红，见图1。
测试，并记录使用2周、4周、6周与8周的数据，见下表1。
表1.测试数据
| 皮肤颜色(红-绿)值a值 | 使用前 | 2w | 4w |
| 实施例2 | 25 | 22 | 21 |
| 实施例3 | 26.1 | 22.5 | 21.3 |
从表1可见，使用者2与使用者3在使用本发明定制的护肤品2-4周后，a值比使用前呈降低趋势。
本发明通过基因测序技术，分析特定基因序列的单核苷酸多态性(SNP)，通过精准的基因位点进行皮肤肤质遗传信息的解读，全面解析受试者肌肤功能生理状态以及各种因素下可能出现的肤质问题，可以根据检测结果选择定制的护肤品。本发明的护肤品具有抗炎修复、增强免疫力、平衡润养、预防敏感、调节水油平衡、净化毛孔，抑制炎症，预防痘痘生成，减少肌肤不适，挺好肌肤耐受性，促进表皮新生修复的优点。
对于该领域技术人员可明了的是，上述具体实施例可于不背离本发明的广义概念下而修改。因此，应明了本发明并非局限于所公开的特定具体实施例，但此意欲包含属于本发明的精神及范畴内的各种变化，即如同所附的权利要求。
Claims (9)
1.一种基于抗炎基因定制护肤品的方法，包括采集用户细胞样本、提取DNA并检测DNA中抗衰老相关基因的多态性，其特征在于，所述的抗炎相关基因包括抗痤疮能力相关基因、抗刺激性皮炎能力相关基因与抗过敏性皮炎能力相关基因。
2.根据权利要求1所述的一种基于抗炎基因定制护肤品的方法，其特征在于，所述的抗痤疮能力相关基因包括RETN、OVOL1、TGFB2与SELL。
3.根据权利要求1所述的一种基于抗炎基因定制护肤品的方法，其特征在于，所述的抗刺激性皮炎能力相关基因包括FLG与TNF。
4.根据权利要求1所述的一种基于抗炎基因定制护肤品的方法，其特征在于，所述的抗过敏性皮炎能力相关基因包括IL16与TNF。
5.一种如权利要求1所述的基于抗炎基因定制的护肤品，其特征在于，所述护肤品的原料按重量份数计包括保湿剂5-10重量份、油脂0.5-6重量份、氨基酸0.1-5重量份、多肽类0.1-6重量份、增溶剂0.2-2重量份、增稠剂0.1-1重量份、皮肤调理剂0.5-5重量份、螯合剂0.1-0.2重量份与水70-90重量份。
6.根据权利要求5所述的基于抗炎基因定制的护肤品，其特征在于，所述保湿剂包含透明质酸钠、水解透明质酸钠、银耳多糖、石斛多糖、β-葡聚糖、海藻糖、甜菜碱、丙二醇、丁二醇、1,2-戊二醇、1,2-己二醇、甘油、双甘油、聚甘油-3、聚甘油-10、甘油聚醚-26、聚季铵盐-51；所述油脂包含角鲨烷、聚二甲基硅氧烷、双-PEG-18甲基醚二甲基硅烷、双-PEG-15甲基醚聚二甲基硅氧烷、橄榄油、霍霍巴油、牛油果树果脂的一种或多种；所述氨基酸包括酪氨酸、苯丙氨酸、胱氨酸、半胱氨酸、色氨酸、肌氨酸、赖氨酸、羟脯氨酸、蛋氨酸、组氨酸、精氨酸、天冬氨酸、苏氨酸、丝氨酸、谷氨酸、脯氨酸、甘氨酸、丙氨酸、缬氨酸、异亮氨酸、亮氨酸、天冬酰胺、谷氨酰胺、葡糖胺、软骨素硫酸钠、吡哆素、生物素、牛磺酸、视黄醇、叶酸、核黄素、烟酰胺、氰钴胺的一种或多种；所述多肽包含寡肽-1、寡肽-2、寡肽-3、寡肽-4，寡肽-5、寡肽-6，肌肽，腺苷，三肽-1、三肽-1铜、三肽-3、五肽-1、五肽-3、六肽-1、六肽-3、六肽-5、六肽-9、六肽-11、九肽-1、棕榈酰三肽-1、棕榈酰三肽-5、乙酰基六肽-8、谷胱甘肽、精氨酸/赖氨酸多肽、棕榈酰四肽-7、乙酰基四肽-2、棕榈酰四肽-2、棕榈酰五肽-4、酵母菌多肽类中的一种或几种的组合。
7.根据权利要求6所述的基于抗炎基因定制的护肤品，其特征在于，针对用户的抗痤疮能力选择加入苦参根提取物与PCA锌。
8.根据权利要求6所述的基于抗炎基因定制的护肤品，其特征在于，针对用户的抗刺激性皮炎能力选择加入裂裥菌素。
9.根据权利要求6所述的基于抗炎基因定制的护肤品，其特征在于，针对用户的抗过敏性皮炎能力选择加入意大利腊菊提取物与粉防己提取物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210994724.7A CN115386643A (zh) | 2022-08-18 | 2022-08-18 | 一种基于抗炎基因定制护肤品的方法与护肤品 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210994724.7A CN115386643A (zh) | 2022-08-18 | 2022-08-18 | 一种基于抗炎基因定制护肤品的方法与护肤品 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115386643A true CN115386643A (zh) | 2022-11-25 |
Family
ID=84121568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210994724.7A Pending CN115386643A (zh) | 2022-08-18 | 2022-08-18 | 一种基于抗炎基因定制护肤品的方法与护肤品 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115386643A (zh) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090042204A1 (en) * | 2006-01-05 | 2009-02-12 | Diane Thiboutot | Acne lesion biomarkers and modulators thereof |
| CN103735682A (zh) * | 2013-12-31 | 2014-04-23 | 周文武 | 一种用于治疗过敏性皮炎的药物及其制备方法 |
| CN105055480A (zh) * | 2015-08-10 | 2015-11-18 | 江苏大学 | 一种意大利腊菊精油纳米脂质体抗菌剂及其制备方法 |
| US20160326587A1 (en) * | 2013-12-19 | 2016-11-10 | King's College London | Ovol1 as a new marker for moderate to severe acne |
| CN106821862A (zh) * | 2017-03-23 | 2017-06-13 | 广州市花安堂生物科技有限公司 | 一种祛痘组合物及其制备方法 |
| CN107828860A (zh) * | 2017-12-12 | 2018-03-23 | 杜立波 | 一种基于基因检测的护肤品定制方法 |
| CN108004329A (zh) * | 2017-12-12 | 2018-05-08 | 杜立波 | 一种改善过敏肤质的护肤品定制方法 |
| CN108950012A (zh) * | 2018-07-27 | 2018-12-07 | 珠海伊斯佳科技股份有限公司 | 一种基于肤质相关基因检测制定个性化护肤方案的方法 |
| CN109953923A (zh) * | 2019-04-25 | 2019-07-02 | 广州珈源日化用品有限公司 | 一种含裂裥菌素、地黄根和松木提取物的头发睫毛生长液 |
| CN111321212A (zh) * | 2020-01-22 | 2020-06-23 | 广州市普森生物科技有限公司 | 皮肤抗痘能力基因检测的引物组合及其应用 |
| CN111944912A (zh) * | 2020-08-28 | 2020-11-17 | 重庆浦洛通基因医学研究院有限公司 | 一种肤质基因检测方法 |
-
2022
- 2022-08-18 CN CN202210994724.7A patent/CN115386643A/zh active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090042204A1 (en) * | 2006-01-05 | 2009-02-12 | Diane Thiboutot | Acne lesion biomarkers and modulators thereof |
| US20160326587A1 (en) * | 2013-12-19 | 2016-11-10 | King's College London | Ovol1 as a new marker for moderate to severe acne |
| CN103735682A (zh) * | 2013-12-31 | 2014-04-23 | 周文武 | 一种用于治疗过敏性皮炎的药物及其制备方法 |
| CN105055480A (zh) * | 2015-08-10 | 2015-11-18 | 江苏大学 | 一种意大利腊菊精油纳米脂质体抗菌剂及其制备方法 |
| CN106821862A (zh) * | 2017-03-23 | 2017-06-13 | 广州市花安堂生物科技有限公司 | 一种祛痘组合物及其制备方法 |
| CN107828860A (zh) * | 2017-12-12 | 2018-03-23 | 杜立波 | 一种基于基因检测的护肤品定制方法 |
| CN108004329A (zh) * | 2017-12-12 | 2018-05-08 | 杜立波 | 一种改善过敏肤质的护肤品定制方法 |
| CN108950012A (zh) * | 2018-07-27 | 2018-12-07 | 珠海伊斯佳科技股份有限公司 | 一种基于肤质相关基因检测制定个性化护肤方案的方法 |
| CN109953923A (zh) * | 2019-04-25 | 2019-07-02 | 广州珈源日化用品有限公司 | 一种含裂裥菌素、地黄根和松木提取物的头发睫毛生长液 |
| CN111321212A (zh) * | 2020-01-22 | 2020-06-23 | 广州市普森生物科技有限公司 | 皮肤抗痘能力基因检测的引物组合及其应用 |
| CN111944912A (zh) * | 2020-08-28 | 2020-11-17 | 重庆浦洛通基因医学研究院有限公司 | 一种肤质基因检测方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102494228B1 (ko) | 효모 추출물의 신규 화장품용 및/또는 기능식품용 또는 피부과용 용도 | |
| CN113041190B (zh) | 抗氧化组合物、制备方法及用途 | |
| BR112015032526B1 (pt) | composições anticaspa e métodos de uso das mesmas | |
| CN115137665A (zh) | 一种具有长效保湿及舒缓功效的组合物及其应用 | |
| JPH09255547A (ja) | 皮膚外用剤 | |
| Iglesia et al. | A multi‐functional anti‐aging moisturizer maintains a diverse and balanced facial skin microbiome | |
| CN115386643A (zh) | 一种基于抗炎基因定制护肤品的方法与护肤品 | |
| KR20230074492A (ko) | 피부 및/또는 점막의 편안함 개선 및/또는 비듬의 출현 개선을 위한 펩타이드의 신규 용도 | |
| de Wet et al. | Bilateral malar milia en plaque as primary presentation of discoid lupus erythematosus | |
| CN115487131A (zh) | 一种日用面部皮肤护肤组合物及其制备方法 | |
| CN108969531B (zh) | 聚乙二醇作为活性成分在制备银屑病治疗药物中的应用及其药物 | |
| US11077045B2 (en) | Blood microperfusion to skin by Shilajit | |
| Abdalla et al. | Evaluation of serum α-MSH Level in Melasma | |
| EP3479826B1 (en) | Application of methyl 4-[9-(6-aminopuryl)]-2(s)-hydroxybutyrate in preparation of medicament for treating psoriasis and vitiligo | |
| Han et al. | Clinical and pathological study of 328 cases of actinic keratosis in eastern Chinese patients | |
| TWI225410B (en) | Use of vitamin C or analogues to increase the level of differentiation and/or proliferation of skin cells | |
| CN114848575B (zh) | 一种精华液及其制备方法 | |
| Summey et al. | Actinic lichen nitidus | |
| Siskou et al. | Coexistence of Lichen Sclerosus Et Atrophicus and Morphea in the Same Lesion: A Case Report | |
| CN116440248B (zh) | 含肽和羟丙基四氢吡喃三醇外用制剂组合物及其制备方法 | |
| CA3104621C (en) | Improvement of blood microperfusion to skin by shilajit | |
| CN115386625A (zh) | 一种基于抗光、污基因定制护肤品的方法与护肤品 | |
| CN111346029B (zh) | 改善皮肤粗糙、皮肤敏感的发酵活性物及其制备方法 | |
| JPH11279072A (ja) | 皮膚外用剤 | |
| Yoon et al. | Acute generalized exanthematous pustulosis induced by velvet antler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |